Biomarker Conferences 2022

Biomarker Conferences 2022

We have curated this list of top Biomarker Conferences to help keep you in touch with the latest trends and innovations. Remember to keep an eye on travel restrictions — and let us know if you’re going to a top conference that is not on our list.


Clinical Biomarkers and Companion Diagnostics

Dates: 21-23 February
Location: San Diego

Website: Clinical Biomarkers and Companion Diagnostics

The promise of precision medicine has been driven by the need to accurately predict patient response to therapy while ensuring drug efficacy and safety. Reducing costs and the time required for drug development is also a driving force in the use of biomarkers. This meeting will cover novel biomarker discovery, clinical and analytical biomarker validation, and the role of biomarkers in clinical decision making and drug-diagnostic co-development.


Clinical Biomarker & CDx Summit Europe

Dates: 27 – 28 April 2022
Location:  London

Website: Clinical Biomarker & CDx Summit Europe

Against the backdrop of complex IVDR changes creating industry-wide uncertainty, CB & CDx Europe returns at an all-important moment in time as Europe’s only end-to-end clinical biomarker and CDx summit. Uniting the entire value chain of precision medicine leaders, here you can find the latest updates, intelligence and clarity to overcome your portfolio planning hurdles.


Biomarkers UK

Dates: 3-5 May 2022
Location: London + virtual

Website: Biomarkers UK

Biomarkers UK is designed to provide forward-looking insights into the latest trends and tools impacting biomarker research. It brings together leading experts from global pharmaceutical organisations, innovative biotech companies and internationally renowned academic institutions working across multiple therapeutic areas and stages of drug development.


Biomarkers and Precision Oncology World Congress

Dates: 20-22 June 2022
Location:  Boston, MA

Website: Biomarkers and Precision Oncology World Congress

This is the longest-running event dedicated to all areas of biomarker research and development spanning the pharmaceutical and diagnostic pipelines. Since 2004, the Congress has emerged as the leading annual meeting where big pharma and biotech drive innovation and collaboration in clinical and translational biomarkers, precision medicine and companion diagnostics, precision oncology and immuno-oncology biomarkers, liquid biopsy, spatial biology and single-cell analysis.


World Clinical Biomarkers & CDx Summit

Dates: September
Location:  TBC

Website: World Clinical Biomarkers & CDx Summit

Across 2 days of comprehensive content, 65+ global expert speakers shared fresh data paired with inspiring stories from innovative partnership collaborations to help you overcome your most pressing challenges and accelerate curative medicine for heterogeneous patient populations.


Biomarkers US

Dates: 3-4 October
Location: San Diego

Website: Biomarkers US

Featuring 40+ presentations, the event brings together over 300 attendees from leading pharma, biotech and academic organisations working in the biomarker industry across multiple therapeutic areas, allowing attendees to gain insights into the latest novel biomarker data and technologies.


Clinical and Translational Biomarkers

Dates: 3 November
Location:  Virtual

Website: Clinical and Translational Biomarkers

Designed for clinical and translational biomarker experts to stay up-to-date with the latest strategies and technologies impacting their workflow, this in-depth conference allows leading scientists to discuss innovative approaches to clinical trial design & strategy, sample management and safety considerations.


Biomarkers for Rare Diseases

Dates: November
Location:  TBC

Website: Biomarkers for Rare Diseases

We aim to define the new standards in digital innovation for clinical transformation. Join 500 + clinical innovators and 40 + Uniting world leaders developing novel therapeutics for rare diseases, we discussed learnings, challenges and future directions at the only summit dedicated to approaches to identify, test and proof clinical biomarkers in rare diseases for regulatory approval. From identifying disease driving biomarkers, robust assay validation, harnessing the latest technologies and demonstrating therapy efficacy, this was the definitive platform to accelerate bench to bedside rare disease development towards regulatory filing and patient populations.

Tell us about your needs

Whether you have general questions about our products and solutions or would like to schedule a demo, our expert team is available to help.

Related Posts